RxDoctor Payments Data

Nancy Colvin

Nurse Practitioner · New Smyrna Beach, FLNPI 1699324087

Payments from drug & device makers

$2,030in general payments, 2019–2025

Across 78 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$611
  • Boehringer Ingelheim$273
  • GSK$249
  • Novo Nordisk$249
  • Amgen$137
  • Lilly USA, LLC$115
  • plus $397 from 11 others

What the payments were for

  • Food & beverage$2,024100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,030 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$29,043
Medicare patients
172
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$56,745
JardianceEmpagliflozin36$44,769
JanuviaSitagliptin Phosphate44$41,978
FarxigaDapagliflozin Propanediol34$32,804
TrulicityDulaglutide25$29,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$27,339
OzempicSemaglutide15$17,983
EliquisApixaban13$8,601
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,438
SymbicortBudesonide/Formoterol Fumarate13$5,297
Albuterol Sulfate HfaAlbuterol Sulfate106$3,729
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,993
Atorvastatin Calcium214$2,263
Omeprazole140$2,192
Amlodipine Besylate238$1,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$115$86,21465 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$611$46,53858 claims
Boehringer IngelheimJardiance$273$44,76936 claims
GSKTrelegy Ellipta$249$27,33928 claims
Novo NordiskOzempic$249$17,98315 claims
PfizerEliquis$24$8,60113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in New Smyrna Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →